News

Hapbee Announces Initial Closing of Upsized Non-Brokered Private Placement of $6.1 Million

Read More

EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries

Read More

Hapbee Technologies Inc. Virtually Opens the Market

Read More

EMulate Therapeutics Announces Poster Presentation of Its Confirmatory Pre-Clinical Pain Study Results at the 15th Annual Pain Therapeutic Summit at Washington, D.C. (Nov 1-3)

Read More

EMulate Therapeutics Announces Positive, Confirmatory Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs

Read More

Hapbee Technologies, Inc.’s (OTCQB:HAPBF) (TSXV:HAPB) interview with Yona Shtern, CEO

Read More

EMulate Therapeutics Announces Positive Pre-Clinical Data in Mental Health Models and First in Human Experience Using its Proprietary Radio Frequency Energy Technology; Preliminary Results Emulate Drug Effects in Rodent Models and in Human Exposures

Read More

EMulate Therapeutics Announces Issuance of Additional U.S. Patent Covering a Therapeutic Device for Cancer and Other Health Indications

Read More

New to The Street TV and Hapbee Technologies, Inc. Sign Contract for 12 Part TV Series Across Syndicated Television Networks

Read More

EMulate Therapeutics Announces Positive Pre-Clinical Data for its ulRFE(R) Technology Targeting Acute and Chronic Pain; Demonstrates Excellent Pain Reducing Effects Without the Use of Chemicals or Drugs

Read More